BioCryst results, upcoming milestones

 —ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) —

—2024 ORLADEYO net revenue expected to be between $380-$400 million—

—Company expects operating profit in 2024, approaching positive EPS and positive cash flow in 2H 2025—

https://www.globenewswire.com/news-release/2024/02/26/2834990/29446/en/BioCryst-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Upcoming-Key-Milestones.html